Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
8th grade Good
|
New words:
accessible, aggressively, answer, ascending, asserting, attention, Barr, bill, borne, breakeven, carbidopa, Catena, chose, classified, comparison, corroborated, counterparty, covenant, Department, devastating, discretion, disrupt, disruptive, dissident, economic, embedded, energy, entitledApproved, environment, erosion, FAS, female, freestanding, FSP, FSPNo, GE, geographic, GlaxoSmithKline, Hatch, Hedging, hierarchy, Ia, Ib, Jersey, Junior, Justice, lesser, levodopa, LP, male, maximize, Maximizing, merger, mitochondria, Monetizing, morphine, narrowed, NJ, overhead, peak, prejudice, proven, quoted, reassigned, reclassification, referendum, repeat, reserve, resistant, resubmit, resveratrol, Sandoz, settle, settled, slate, stake, surviving, tamper, Tang, threatening, trough, turn, unadjusted, unobservable, viii, waived, Waxman, workforce, worth
Removed:
addressed, affiliated, Alpharma, angina, announcement, branded, bringing, carryforward, Certificate, codeine, congestive, consisting, consolidated, desired, discontinuation, edema, eighteen, enhanced, epilepsy, essentially, exchanged, extension, forma, formulate, Frova, heart, hypertension, improve, injection, innovative, intensity, interval, intramuscular, jointly, largely, leadership, leverage, Lidoderm, migraine, network, notified, Nubain, occurring, opening, outline, pathway, Percocet, Percodan, permitted, pilot, plasma, precise, principle, Prism, pro, promissory, range, ranging, redeemed, reformulated, reformulating, repaid, request, revised, selecting, selectively, solution, specialist, sterile, tramadol, treated, treating, unusual, unvested, validation, wide, window
Filing tables
Filing exhibits
- 10-K Annual report
- 10.26 EX-10.26 Summary of Executive Officer Bonus Program
- 10.27 EX-10.27 Summary of the Director Compensation Program
- 10.34 EX-10.34 Form of Executive Retention Agreements
- 23 EX-23 Consent of Ernst & Young LLP
- 31 EX-31 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 302
- 32 EX-32 Certification of Principal Executive Officer and Principal Financial Officer Pursuant to Section 906
Related press release
PPCO similar filings
Filing view
External links
Exhibit 32
CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND PRINCIPAL FINANCIAL OFFICER
PURSUANT TO RULE 13a-14(b) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350
PURSUANT TO RULE 13a-14(b) OF THE
SECURITIES EXCHANGE ACT OF 1934 AND 18 U.S.C. SECTION 1350
In connection with the Annual Report on Form 10-K of Penwest Pharmaceuticals Co. (the “Company”) for the fiscal year ended December 31, 2008 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), the undersigned, Jennifer L. Good, President and Chief Executive Officer of the Company, hereby certifies, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1) The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Date: March 12, 2009 | /s/ Jennifer L. Good | |||
Jennifer L. Good | ||||
President and Chief Executive Officer (Principal Executive Officer and Principal Financial Officer) | ||||